

贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌的临床观察

常琳, 宗红, 王留兴, 樊青霞, 王瑞林

450052 郑州, 郑州大学第一附属医院肿瘤科

Clinical Study of Bevacizumab Combined with FOLFIRI Regimen in Treatment of Advanced Colorectal Cancer

CHANG Lin, ZONG Hong, WANG Liuxing, FAN Qingxia, WANG Ruilin

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

- 摘要
- 参考文献
- 相关文章

全文: PDF (502 KB) HTML (KB) 输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的 观察贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌的临床疗效及不良反应, 评价其有效性和安全性。

方法 回顾性分析2009年-2011年收治的经病理学确诊的晚期结直肠癌病例42例, 其中22例采用贝伐单抗联合FOLFIRI方案治疗(研究组), 20例采用单纯FOLFIRI方案治疗(对照组), 观察其疗效和不良反应, 并进行随访。

结果 42例患者均可评价疗效和不良反应。研究组和对照组的客观有效率分别为45.4%, 20.0%; 中位生存期分别为15.7月, 12.0月, 差异均具有统计学意义($P<0.05$); 治疗后两组的肿瘤标志物均有所下降, 其中仅研究组CEA差异具有统计学意义($P<0.05$), 余均无统计学意义($P>0.05$)。研究组较对照组增加的不良反应主要有高血压、出血等, 发生率分别为27.3%、22.7%, 但均为I~II级, 经药物治疗后均可控制, 不影响化疗的连续性。

结论 贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌能够提高疗效, 延长生存时间, 且患者耐受性较好, 具有较好的临床应用前景。

关键词: 贝伐单抗 FOLFIRI方案 晚期结直肠癌 临床疗效 不良反应 单克隆抗体

Abstract:

Objective To observe and evaluate the clinical efficacy, toxicity and safety of bevacizumab plus FOLFIRI regimen in the treatment of advanced colorectal cancer.

Methods Forty-two advanced colorectal cancer cases were collected from 2009 to 2011 and confirmed by pathology were divided into 2 groups to receive bevacizumab plus FOLFIRI (the study group) and FOLFIRI only treatment (the control group). The efficacy side effects and survival time in two groups were observed and compared.

Results Forty-two patients were all evaluable for efficacy and adverse reactions. The objective response rate of the study and control group was 45.4% and 20.0% respectively; the median overall survival of two groups was 15.7 and 12.0 months. The difference were all statistically significant ($P<0.05$). After treatment, there were three kinds of decreased tumor markers in two groups, and significant difference of CEA level was just identified in study group ($P<0.05$). The toxicity related to bevacizumab includes high blood pressure and bleeding, with the incidence of 27.3% and 22.7%, respectively, but all were grade I or II, they could be controlled after drug treatment, and didn't affect the continuity of the chemotherapy.

Conclusion Bevacizumab combined with FOLFIRI regimen can improve efficacy in the treatment of advanced colorectal cancer patients, and the adverse effects were well tolerated.

Key words: Bevacizumab) " href="#">

Bevacizumab FOLFIRI regimen; Advanced colorectal cancer; Clinical efficacy; Monoclonal antibodies

) " href="#">Toxic response;

Monoclonal antibodies

服务

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert
- ▶ RSS

作者相关文章

- ▶ 常琳
- ▶ 宗红
- ▶ 王留兴
- ▶ 樊青霞
- ▶ 王瑞林

收稿日期: 2012-08-13;

通讯作者: 王留兴, E-mail: wx2246@yahoo.com.cn E-mail: wx2246@yahoo.com.cn

作者简介: 常琳(1987-), 女, 硕士在读, 主要从事恶性肿瘤的治疗研究

引用本文:

常琳,宗红,王留兴等. 贝伐单抗联合FOLFIRI方案治疗晚期结直肠癌的临床观察[J]. 肿瘤防治研究, 2013, 40(05): 485-488.

CHANG Lin,ZONG Hong,WANG Liuxing et al.

Clinical Study of Bevacizumab Combined with FOLFIRI Regimen in Treatment of Advanced Colorectal Cancer

[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 485-488.

没有本文参考文献

- [1] 钟薇, 古力米热·布然江, 古丽娜·库尔班. 外阴癌术前适形调强放射治疗的临床观察[J]. 肿瘤防治研究, 2012, 39(7): 863-864.
- [2] 沈文斌, 祝淑钗, 高红梅, 李娟, 苏景伟, 刘志坤, 李幼梅, 万钧. 三维适形大分割放射治疗局部中晚期非小细胞肺癌的不良反应与长期生存分析[J]. 肿瘤防治研究, 2012, 39(5): 577-581.
- [3] 张华;冯卫能;邓燕明;冼海兵. 培美曲塞联合顺铂一线治疗晚期非鳞状非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 2012, 39(1): 88-90.
- [4] 张红梅, 徐伶俐, 安广宇. 贝伐单抗联合FOLFIRI方案一线治疗转移性结直肠癌的临床评价[J]. 肿瘤防治研究, 2012, 39(08): 1001-1004.
- [5] 武海松;邢磊;袁野. 改良FOLFOX方案时辰化疗治疗晚期胃肠癌的临床观察[J]. 肿瘤防治研究, 2011, 38(8): 944-946.
- [6] 王志军;吴月兵. 利妥昔单抗治疗弥漫大B细胞淋巴瘤的临床观察[J]. 肿瘤防治研究, 2011, 38(8): 947-949.
- [7] 孙力超;赵璇;孙立新;遇珑;杨治华;冉宇靓. 肝癌干细胞抗体靶向治疗的实验[J]. 肿瘤防治研究, 2011, 38(6): 609-614.
- [8] 寇小格;梁东良;李小瑞. 参一胶囊联合卡培他滨治疗晚期乳腺癌临床观察[J]. 肿瘤防治研究, 2011, 38(3): 319-321.
- [9] 安云婷;李霞;喻金梅;郭晨. 氟尿嘧啶缓释植入剂与组织间插植在宫颈癌中的疗效观察[J]. 肿瘤防治研究, 2011, 38(2): 202-205.
- [10] 李嵘;刘秀峰;何泽明;华海清;王琳;陈映霞. 伊立替康联合替加氟持续静脉滴注治疗晚期结直肠癌的临床观察[J]. 肿瘤防治研究, 2011, 38(12): 1419-1422.
- [11] 胡正操;李永杰;陈素梅. 岩舒减轻化疗不良反应的临床观察[J]. 肿瘤防治研究, 2011, 38(12): 1429-1430.
- [12] 姜林;;孔庆志;胡贤主. 全身伽玛刀联合DP方案治疗中晚期肺癌的疗效观察[J]. 肿瘤防治研究, 2011, 38(12): 1431-1433.
- [13] 左强;罗宇玲;罗荣城. ¹³¹I标记抗CD20单克隆抗体不同给药途径对荷瘤裸鼠的放射免疫治疗实验[J]. 肿瘤防治研究, 2011, 38(1): 35-37.
- [14] 胡志全;苏耀武;王志华;曾星;刘双林;庄乾元;杨为民;刘继红;叶章群. 索拉非尼治疗转移性肾癌的不良不良反应[J]. 肿瘤防治研究, 2010, 37(5): 589-591.
- [15] 原少斐;陈筱婷;汪森明;杜红延;李明. 抗人微管不稳定蛋白单克隆抗体的制备及鉴定[J]. 肿瘤防治研究, 2009, 36(6): 466-469.